Combination systemic therapies with immune checkpoint inhibitors in biliary tract cancer: effective but not enough?

Affiliations

¹ Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello," I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
² Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy.

Editorial

Alessandro Rizzo et al. Expert Rev Gastroenterol Hepatol. 2022 Apr.

. 2022 Apr;16(4):307-310.

doi: 10.1080/17474124.2022.2055548. Epub 2022 Mar 22.

¹ Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello," I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
² Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy.

No abstract available

Keywords: Immunotherapy; biliary tract cancer; cholangiocarcinoma; durvalumab; pembrolizumab.

Comment on

Current and emerging therapies for advanced biliary tract cancers.
Kam AE, Masood A, Shroff RT. Kam AE, et al. Lancet Gastroenterol Hepatol. 2021 Nov;6(11):956-969. doi: 10.1016/S2468-1253(21)00171-0. Lancet Gastroenterol Hepatol. 2021. PMID: 34626563 Review.